Aptose Biosciences is a clinical-stage biotechnology company developing personalized therapies to address unmet medical needs in oncology, with a particular focus on hematologic malignancies. Aptose is advancing new therapeutics focused on well validated and novel drug targets on the leading edge of cancer research, coupled with validated biomarkers to identify the optimal patient population for our products. The company's small molecule cancer therapeutics pipeline includes products designed for potent single agent activity and to enhance the efficacy of existing anti-cancer therapies without overlapping toxicities. Aptose Biosciences Inc. is listed on NASDAQ under the symbol APTO and on the TSX under the symbol APS.
No articles found.
We are developing nalbuphine ER to treat serious neurologically mediated condition...
We are developing nalbuphine ER to treat seriou...
Tricida, Inc. , Tricida, Inc. , is a pharmaceutical company focused on the develop...
Tricida, Inc. , Tricida, Inc. , is a pharmaceut...
TransMedics is a commercial-stage medical technology company transforming organ tr...
TransMedics is a commercial-stage medical techn...
Liquidia is a late-stage clinical biopharmaceutical company focused on the develop...
Liquidia is a late-stage clinical biopharmaceut...
Otsuka Holdings Co Ltd is a pharmaceutical company. The Company manufactures, sell...
Otsuka Holdings Co Ltd is a pharmaceutical comp...
Hepion Pharmaceuticals (Nasdaq: HEPA) is a clinical stage biopharmaceutical compan...
Hepion Pharmaceuticals (Nasdaq: HEPA) is a clin...
Athenex is a global oncology focused biopharmaceutical company dedicated to the di...
Athenex is a global oncology focused biopharmac...
MacroGenics is a clinical-stage biopharmaceutical company focused on discovering a...
MacroGenics is a clinical-stage biopharmaceutic...
Join the National Investor Network and get the latest information with your interests in mind.